Compare Stocks: XENE, ASND, EXEL, and SMMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$223.28 -6.0%	$253.72	$186.05 ▼ $282.15	$13.94B	0.35	692,639 shs	477,744 shs
EXEL Exelixis	$56.61 -2.6%	$55.51	$33.76 ▼ $59.72	$14.02B	0.42	2.63 million shs	533,866 shs
SMMT Summit Therapeutics	$16.47 -3.8%	$14.78	$12.07 ▼ $29.23	$13.12B	-1.24	4.37 million shs	2.30 million shs
XENE Xenon Pharmaceuticals	$36.38 -6.9%	$60.98	$35.97 ▼ $72.66	$3.52B	0.61	1.32 million shs	1.41 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	-0.01%	-0.92%	-6.21%	-0.18%	+20.95%
EXEL Exelixis	+1.63%	+2.20%	+7.53%	+9.99%	+46.92%
SMMT Summit Therapeutics	+1.30%	-1.61%	+30.09%	+20.14%	-10.37%
XENE Xenon Pharmaceuticals	+0.26%	-30.54%	-35.68%	-29.67%	+4.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$223.28 -6.0%	$253.72	$186.05 ▼ $282.15	$13.94B	0.35	692,639 shs	477,744 shs
EXEL Exelixis	$56.61 -2.6%	$55.51	$33.76 ▼ $59.72	$14.02B	0.42	2.63 million shs	533,866 shs
SMMT Summit Therapeutics	$16.47 -3.8%	$14.78	$12.07 ▼ $29.23	$13.12B	-1.24	4.37 million shs	2.30 million shs
XENE Xenon Pharmaceuticals	$36.38 -6.9%	$60.98	$35.97 ▼ $72.66	$3.52B	0.61	1.32 million shs	1.41 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	-0.01%	-0.92%	-6.21%	-0.18%	+20.95%
EXEL Exelixis	+1.63%	+2.20%	+7.53%	+9.99%	+46.92%
SMMT Summit Therapeutics	+1.30%	-1.61%	+30.09%	+20.14%	-10.37%
XENE Xenon Pharmaceuticals	+0.26%	-30.54%	-35.68%	-29.67%	+4.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$310.75	39.18% Upside
EXEL Exelixis	2.35	Hold	$50.29	-11.17% Downside
SMMT Summit Therapeutics	2.41	Hold	$25.91	57.27% Upside
XENE Xenon Pharmaceuticals	2.94	Moderate Buy	$70.93	94.98% Upside

Current Analyst Ratings Breakdown

Latest XENE, ASND, EXEL, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/23/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/22/2026	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/18/2026	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/18/2026	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$69.00 ➝ $64.00
9/18/2026	XENE Xenon Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$90.00 ➝ $46.00
9/18/2026	XENE Xenon Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$90.00 ➝ $46.00
9/18/2026	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $70.00
9/18/2026	XENE Xenon Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$71.00 ➝ $55.00
9/18/2026	XENE Xenon Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$97.00 ➝ $90.00
9/18/2026	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$78.00 ➝ $60.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$814.57M	17.10	N/A	N/A	($2.97) per share	-75.18
EXEL Exelixis	$2.32B	6.05	$3.00 per share	18.90	$8.06 per share	7.02
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.85 per share	N/A
XENE Xenon Pharmaceuticals	$7.50M	468.91	N/A	N/A	$7.53 per share	4.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$258M	$12.89	17.34	25.17	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	17.79	15.22	1.70	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)
XENE Xenon Pharmaceuticals	-$345.91M	-$4.74	N/A	N/A	N/A	N/A	-43.98%	-41.72%	11/2/2026 (Estimated)

Latest XENE, ASND, EXEL, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/19/2026	Q3 2026	SMMT Summit Therapeutics	-$0.28	N/A	N/A	N/A	$0.07 million	N/A
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	0.27	2.99	2.32
EXEL Exelixis	N/A	3.46	3.38
SMMT Summit Therapeutics	N/A	6.96	6.96
XENE Xenon Pharmaceuticals	N/A	21.01	21.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
EXEL Exelixis	85.27%
SMMT Summit Therapeutics	4.61%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
EXEL Exelixis	2.60%
SMMT Summit Therapeutics	83.50%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
SMMT Summit Therapeutics	265	797.75 million	131.63 million	Optionable
XENE Xenon Pharmaceuticals	370	96.67 million	93.85 million	Optionable

XENE, ASND, EXEL, and SMMT Headlines

Recent News About These Companies

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

September 22 at 12:23 AM | businesswire.com

Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?

September 22 at 8:50 PM | insidermonkey.com

Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)

September 22 at 6:18 PM | prnewswire.com

Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate

September 22 at 9:00 AM | seekingalpha.com

Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

September 22 at 7:47 AM | globenewswire.com

Xenon stock lost 30%, but the FDA story is more complicated

September 21 at 11:37 PM | msn.com

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

September 21 at 4:30 PM | financialpost.comF

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

September 21 at 4:01 PM | globenewswire.com

Xenon shares slide more than 30% as company pauses psychiatry trial enrollment

September 21 at 1:36 PM | thepharmaletter.comT

Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment

September 21 at 1:36 PM | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Sees Unusually-High Trading Volume - Time to Buy?

September 21 at 12:19 PM | marketbeat.com

Xenon Pharmaceuticals Inc (XENE)

September 20 at 2:39 PM | za.investing.com

Robert W. Baird Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

September 20 at 3:22 AM | americanbankingnews.com

Needham & Company LLC Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

September 20 at 3:22 AM | americanbankingnews.com

Royal Bank Of Canada Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $70.00

September 20 at 2:40 AM | americanbankingnews.com

Wedbush Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00

September 20 at 2:02 AM | americanbankingnews.com

Goldman Sachs Sticks to Its Buy Rating for Xenon (XENE)

September 19, 2026 | theglobeandmail.com

Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data

September 19, 2026 | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Downgraded to "Strong Sell" Rating by Wall Street Zen

September 19, 2026 | marketbeat.com

Xenon: The Psychiatry Pause Matters More Than You Think (Rating Downgrade)

September 18, 2026 | seekingalpha.com

XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial

September 18, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE, ASND, EXEL, and SMMT Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$223.28 -14.29 (-6.02%)

As of 01:53 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis NASDAQ:EXEL

$56.61 -1.54 (-2.65%)

As of 01:53 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Summit Therapeutics NASDAQ:SMMT

$16.47 -0.65 (-3.77%)

As of 01:53 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Xenon Pharmaceuticals NASDAQ:XENE

$36.38 -2.71 (-6.93%)

As of 01:53 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XENE, ASND, EXEL, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XENE, ASND, EXEL, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XENE, ASND, EXEL, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE, ASND, EXEL, and SMMT Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Summit Therapeutics NASDAQ:SMMT

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XENE, ASND, EXEL, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XENE, ASND, EXEL, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XENE, ASND, EXEL, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE, ASND, EXEL, and SMMT Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Summit Therapeutics NASDAQ:SMMT

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools